Computational modeling of interactions between multiple myeloma and the bone microenvironment

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Wang, Yan ^a   Pivonka, Peter ^b   Buenzli, Pascal R ^b   Smith, David W ^b   Dunstan, Colin R ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ARTICLE; BONE CELL; BONE REMODELING; BONE STRUCTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL POPULATION; COMPUTER SIMULATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; INTRACELLULAR SIGNALING; MULTIPLE MYELOMA; OSTEOLYSIS; POSITIVE FEEDBACK; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; BONE; BONE TUMOR; CELL COUNT; DISEASE COURSE; FEEDBACK SYSTEM; HUMAN; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TUMOR VOLUME;

BONE AND BONES; BONE NEOPLASMS; CELL COUNT; COMPUTER SIMULATION; DISEASE PROGRESSION; FEEDBACK, PHYSIOLOGICAL; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; ORGAN SIZE; TIME FACTORS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 80555154409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027494     Document Type: Article

References (90)

1. Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, et al. (2008) Model structure and control of bone remodeling: A theoretical study. Bone 43: 249-263.
2. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, et al. (2005) Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochemical and Biophysical Research Communications 338: 687-693.
3. Silbermann R, Roodmann GD, (2010) Clinical Presentation of Myeloma Bone Disease. In: Roodman GD, editors. Myeloma Bone Disease New York Humana Press.
4. Nau KC, Lewis WD, (2008) Multiple Myeloma: Diagnosis and Treatment. American Family Physician 78: 853-859.
5. Roodman GD, (2008) Pathogenesis of myeloma bone disease. Leukemia 23: 435-441.
6. Yeh HS, Berenson JR, (2006) Myeloma bone disease and treatment options. European Journal of Cancer 42: 1554-1563.
7. Harada SI, Rodan GA, (2003) Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
8. Parfitt AM, (1994) Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. Journal of Cellular Biochemistry 55: 273-286.
9. Manolagas SC, (2000) Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr Rev 21: 115-137.
10. Rodan GA, Martin TJ, (2000) Therapeutic Approaches to Bone Diseases. Science 289: 1508.
11. Terpos E, Dimopoulos MA, (2005) Myeloma bone disease: pathophysiology and management. Annals of Oncology 16: 1223-1231.
12. Edwards CM, Zhuang J, Mundy GR, (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
13. Mundy GR, (2002) Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
14. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
15. Terpos E, Dimopoulos MA, Sezer O, (2007) The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21: 1875-1884.
16. Kuehl WM, Bergsagel PL, (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187.
17. Ayati B, Edwards C, Webb G, Wikswo J, (2010) A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biology Direct 5: 28.
18. Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, et al. (2010) Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology 262: 306-316.
19. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ, (2004) Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. Journal of Theoretical Biology 229: 293-309.
20. Buenzli PR, Pivonka P, Smith DW, (2011) Spatio-temporal structure of cell distribution in cortical Bone Multicellular Units: A mathematical model. Bone 48: 918-926.
21. Caplan AI, (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. Journal of Cellular Physiology 213: 341-347.
22. Muraglia A, Cancedda R, Quarto R, (2000) Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 113: 1161-1166.
23. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC, (2007) Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Journal of Cellular Biochemistry 101: 950-968.
24. Wong PKK, Campbell IK, Egan PJ, Ernst M, Wicks IP, (2003) The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis & Rheumatism 48: 1177-1189.
25. Liu XH, Kirschenbaum A, Yao S, Levine AC, (2005) Cross-Talk between the Interleukin-6 and Prostaglandin E2 Signaling Systems Results in Enhancement of Osteoclastogenesis through Effects on the Osteoprotegerin/Receptor Activator of Nuclear Factor-kappa B (RANK) Ligand/RANK System. Endocrinology 146: 1991-1998.
26. Teoh G, Anderson KC, (1997) Interaction of tumor and Host Cells with Adhesion and Extracellular Matrix Molecules in the Development of Multiple Myeloma. Hematology/Oncology Clinics of North America 11: 27-42.
27. Kwan Tat S, Marc P, Sandrine T, Dominique H, Yannick F, (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 15: 49-60.
28. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, et al. (2003) Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7.
29. Kawasaki K, Gao Y-H, Yokose S, Kaji Y, Nakamura T, et al. (1997) Osteoclasts Are Present in gp130-Deficient Mice. Endocrinology 138: 4959-4965.
30. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, et al. (1994) Impaired Immune and Acute-phase Responses in Interleukin-6-deficient Mice. Nature 368: 339-343.
31. Franchimont N, Wertz S, Malaise M, (2005) Interleukin-6: An osteotropic factor influencing bone formation? Bone 37: 601-606.
32. Lauta VM, (2001) Interleukin-6 and the Network of Several Cytokines in Multiple Myeloma: an Overview of Clinical and Experimental Data. Cytokine 16: 79-86.
33. Bataille R, Chappard D, Klein B, (1992) The critical role of interleukin-6, interleukin-1β and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma. International Journal of Clinical & Laboratory Research 21: 283-287.
34. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112.
35. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, et al. (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 87: 1928-1938.
36. Klein B, Zhang XG, Lu ZY, Bataille R, (1995) Interleukin-6 in human multiple myeloma. Blood 85: 863-872.
37. Trikha M, Corringham R, Klein B, Rossi JF, (2003) Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence. Clin Cancer Res 9: 4653-4665.
38. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, et al. (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100: 3002-3007.
39. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, et al. (2000) T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. British Journal of Haematology 110: 203-209.
40. Kunzmann V, Bauer E, Feurle J, Tony FWHP, Wilhelm M, (2000) Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392.
41. Lin WW, Karin M, (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation 117: 1175-1183.
42. Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M, (2005) Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19: 1729-1738.
43. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, et al. (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671-675.
44. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, et al. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202.
45. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, et al. (2003) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 123: 106.
46. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T, (2009) Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production. Journal of Bone and Mineral Metabolism 27: 16-23.
47. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, et al. (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525.
48. Qiang YW, Shaughnessy JD Jr, Yaccoby S, (2008) Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-382.
49. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N Engl J Med 349: 2483-2494.
50. T, Abe M, Asano J, Hara T, Kitazoe K, et al. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165.
51. Gjuvsland A, Hayes B, Omholt S, Carlborg O, (2007) Statistical epistasis is a generic feature of gene regulatory networks. Genetics 175: 411- 420.
52. Scholten JD, Zimmerman KK, Oxender MG, Leonard D, Sebolt-Leopold J, et al. (1997) Synergy between Anions and Farnesyldiphosphate Competitive Inhibitors of Farnesyl:Protein Transferase. Journal of Biological Chemistry 272: 18077-18081.
53. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, et al. (1994) Reproducible Obtaining of Human Myeloma Cell-Lines as a Model for Tumor Stem-Cell Study in Human Multiple-Myeloma. Blood 83: 3654-3663.
54. Pennisi A, Li X, Ling W, Khan S, Zangari M, et al. (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology 84: 6-14.
55. Dingli D, Offord C, Myers R, Peng KW, Carr TW, et al. (2009) Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther.
56. Ideta AM, Tanaka G, Takeuchi T, Aihara K, (2008) A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer. Journal of Nonlinear Science 18: 593-614.
57. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 121: 749-757.
58. Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, (2004) Myeloma: Biology and Management. Philadelphia Elsevier Inc. (USA).
59. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, et al. (2005) International Staging System for Multiple Myeloma. J Clin Oncol 23: 3412-3420.
60. Harousseau J-L, Moreau P, (2009) Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 360: 2645-2654.
61. Bentele M, Lavrik I, Ulrich M, Stober S, Heermann DW, et al. (2004) Mathematical Modeling Reveals Threshold Mechanism in CD95-Induced Apoptosis. The Journal of Cell Biology 166: 839-851.
62. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, et al. (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology 116: 278-290.
63. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, et al. (2003) Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma. Cancer Research 63: 287-289.
64. Belch AR, Bergsagel DE, Wilson K, Oreilly S, Wilson J, et al. (1991) Effect of Daily Etidronate on the Osteolysis of Multiple-Myeloma. Journal of Clinical Oncology 9: 1397-1402.
65. Kyle RA, Jowsey J, Kelly PJ, Taves DR, (1975) Multiple-Myeloma Bone-Disease- Comparative Effect of Sodium-Fluoride and Calcium-Carbonate or Placebo. New England Journal of Medicine 293: 1334-1338.
66. Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, et al. (2000) Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. European Journal of Haematology 64: 121-129.
67. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, et al. (1997) Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. British Journal of Haematology 97: 641-648.
68. Alexandrakis MG, Passam FH, Malliaraki N, Katachanakis C, Kyriakou DS, et al. (2002) Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clinica Chimica Acta 325: 51-57.
69. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, et al. (2003) Soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069.
70. Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T, (2007) Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92: 1000-1001.
71. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, et al. (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1α) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology 126: 686-689.
72. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, et al. (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology 135: 688-692.
73. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, et al. (2002) Serum Osteoprotegerin Levels in Healthy Controls and Cancer Patients. Clinical Cancer Research 8: 2306-2310.
74. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, et al. (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269-2271.
75. Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, et al. (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity. American Journal of Hematology 72: 229-233.
76. Cristy M, (1981) Active Bone Marrow Distribution as a Function of Age in Humans. Physics in Medicine and Biology 26: 389-400.
77. Lerner UH, (2004) New Molecules in the Tumor Necrosis Factor Ligand and Receptor Superfamilies with Importance for Physiological and Pathological Bone Resorption. Critical Reviews in Oral Biology & Medicine 15: 64-81.
78. Cowin SC, (2001) Bone mechanics handbook, Second Edition. New York, CRC Press LLC.
79. Salmon SE, Smith BA, (1970) Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. The Journal of Clinical Investigation 49: 1114-1121.
80. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, et al. (1990) Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 86: 1976-1984.
81. Schmitt CP, Huber D, Mehls O, Maiwald J, Stein G, et al. (1998) Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 9: 1832-1844.
82. Van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, et al. (1996) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. The Journal of Clinical Investigation 98: 1441-1448.
83. Fan X, Roy E, Zhu L, Murphy TC, Ackert-Bicknell C, et al. (2004) Nitric Oxide Regulates Receptor Activator of Nuclear Factor-kappa B Ligand and Osteoprotegerin Expression in Bone Marrow Stromal Cells. Endocrinology 145: 751-759.
84. Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, et al. (2003) Disabling of RANK receptor complex by novel osteoprotegerin like peptidomimetics restores bone loss in-vivo. JBC.
85. Wols HAM, Underhill GH, Kansas GS, Witte PL, (2002) The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. Journal of Immunology 169: 4213-4221.
86. Zwartz G, Chigaev A, Foutz T, Larson RS, Posner R, et al. (2004) Relationship between Molecular and Cellular Dissociation Rates for VLA-4/VCAM-1 Interaction in the Absence of Shear Stress. Biophysical Journal 86: 1243-1252.
87. Chigaev A, Blenc AM, Braaten JV, Kumaraswamy N, Kepley CL, et al. (2001) Real Time Analysis of the Affinity Regulation of α4-Integrin. Journal of Biological Chemistry 276: 48670-48678.
88. Corso A, Dovio A, Rusconi C, Sartori ML, Klersy C, et al. (2004) Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia 18: 1555-1557.
89. Jakob C, Zavrski I, Heider U, Brux B, Eucker J, et al. (2002) Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. European Journal of Haematology 69: 37-42.
90. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC, (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098.